Forecast Of The Day: Abbott’s Nutritionals Revenue

+32.01%
Upside
115
Market
152
Trefis
ABT: Abbott Laboratories logo
ABT
Abbott Laboratories

What?

Abbott’s (NYSE:ABT) Nutritionals Revenue has risen from around $7.4 billion in 2019 to about $7.7 billion in 2020. Trefis expects the metric to rise to about $8.4 billion in 2021 and to about $8.7 billion in 2022.

Why?

Relevant Articles
  1. This Medical Devices Company Is A Better Pick Over Abbott Stock
  2. This Healthcare Company Is A Better Pick Over Abbott Stock
  3. Should You Buy Abbott Stock After Its Recent Fall?
  4. What’s The Outlook For Covid-19 Testing Stocks As Omicron Wave Fades
  5. Will Abbott Stock Rise After Its Q4 Results?
  6. Why Covid-19 Testing Stocks Are Selling Off Despite Surging Demand

We expect growth to be driven by higher demand from emerging markets and the company’s investments into new product development.

So What?

We think the projected growth is largely priced into ABT stock. We value ABT at about $142 per share, roughly in line with the current market price.

See Our Complete Analysis For Abbott

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.

 Returns Dec 2021
MTD [1]
2021
YTD [1]
2017-21
Total [2]
 ABT Return 6% 23% 251%
 S&P 500 Return -3% 21% 104%
 Trefis MS Portfolio Return -1% 42% 283%

[1] Month-to-date and year-to-date as of 12/20/2021
[2] Cumulative total returns since 2017

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates